All In Biotech

Drug Trial Radar · NCT07782775

A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants

A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period Crossover, Bioequivalence Study of Efgartigimod PH20 SC Administered Via Autoinjector Versus Prefilled Syringe in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jun 19, 2026

Primary completion

Sep 23, 2026

Study completion Sep 23, 2026

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to compare the amount of efgartigimod in the blood over time after it is injected via Prefilled syringe (PFS) and Autoinjector (AI). The study will comprise 2 study periods of 3 weeks each. Each participant receives both efgartigimod PH20 SC AI and PFS treatments, in a different order. Participants will be in the study for up to approximately 9 weeks.

Conditions

  • Healthy Volunteer
  • Healthy Adult Participants

Interventions

  • Efgartigimod PH20 SC via PFSBiological

    Subcutaneous injection of empasiprubart via Prefilled syringe (PFS)

  • Efgartigimod PH20 SC via AIBiological

    Subcutaneous injection of empasiprubart via Autoinjector (AI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary PK parameter: CmaxTime frame: Up to 9 weeks
  2. Primary PK parameter: AUC0-infTime frame: Up to 9 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Montreal, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.